Perinatal Inflammatory Biomarkers and Respiratory Disease in Preterm Infants - 22/06/22
, Sharon A. McGrath-Morrow, MD, MBA 2, Megan Griffiths, MD 3, Raul Chavez-Valdez, MD 1, Charlamaine Parkinson, RN, MSc 1, Jie Zhu, BS 1, Frances J. Northington, MD 1, Ernest M. Graham, MD 4, Allen D. Everett, MD 1Abstract |
Objective |
To measure plasma levels of vascular endothelial growth factor (VEGF) and several cytokines (Interleukin [IL]-6 IL-8, IL-10) during the first week of life to examine the relationship between protein expression and likelihood of developing respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD).
Study design |
Levels of IL-6, IL-8, IL-10, and VEGF were measured from plasma obtained from preterm patients during the first week of life. Newborns were recruited from a single center between April 2009 and April 2019. Criteria for the study included being inborn, birth weight of less than 1500 grams, and a gestational age of less than 32 weeks at birth.
Results |
The development of RDS in preterm newborns was associated with lower levels of VEGF during the first week of life. Higher plasma levels of IL-6 and IL-8 plasma were associated with an increased likelihood and increased severity of BPD at 36 weeks postmenstrual age. In contrast, plasma levels of VEGF, IL-6, IL-8, and IL-10 obtained during the first week of life were not associated with respiratory symptoms and acute care use in young children with BPD in the outpatient setting.
Conclusions |
During the first week of life, lower plasma levels of VEGF was associated with the diagnosis of RDS in preterm infants. Preterm infants with higher levels of IL-6 and IL-8 during the first week of life were also more likely to be diagnosed with BPD. These biomarkers may help to predict respiratory morbidities in preterm newborns during their initial hospitalization.
Le texte complet de cet article est disponible en PDF.Abbreviations : BPD, IL, LLOD, NICU, RDS, ULOD, VEGF
Plan
| Supported by National Institutes of Health National Institute of Child Health and Human Development R01HD086058 [to A.E., F.N., and E.G.], National Institute of Neurological Disorders and Stroke KO8NS096115 [to R.C.-V.], and the Thomas-Wilson Foundation [to R.C.-V.]. The authors declare no conflicts of interest. |
Vol 246
P. 34 - juillet 2022 Retour au numéro
Article précédent
- Rates and Determinants of Home Nasogastric Tube Feeding in Infants Born Very Preterm
- Belal Alshaikh, Kamran Yusuf, Donna Dressler-Mund, Ayman Abou Mehrem, Sajit Augustine, Jaya Bodani, Eugene Yoon, Prakesh Shah, Canadian Neonatal Network (CNN) and Canadian Preterm Birth Network (CPTBN) Investigators
- A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome
- Carlo Dani, Gyula Talosi, Annalisa Piccinno, Virginia Maria Ginocchio, Gyorgy Balla, Anna Lavizzari, Zbynek Stranak, Eloisa Gitto, Stefano Martinelli, Richard Plavka, Barbara Krolak-Olejnik, Gianluca Lista, Francesca Spedicato, Giorgia Ciurlia, Debora Santoro, David Sweet, CURONEB Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?